← Top stories
Broker call▲ Bullish for Dr Reddy's
Dr. Reddy's shares upgraded by Citi after three years, target raised; Stock gains
The brief
- Citi upgraded Dr. Reddy’s after three years and raised its target price
- Citi said Abatacept acceptance indicated the toughest biosimilar development hurdles were behind the company
- A more positive biosimilar outlook may support Dr. Reddy’s shares